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Supplemental	Figure	1:		1	
A)	 Quantification	 of	 hepatic	 Sirius	 red	 staining.	 Quantified	 hepatic	 Sirius	 red	 stainings	2	
represented	in	Figure	1	were	analyzed	using	3DHISTECH	Ltd.	Software.	Quantified	Sirius	red	3	
stainings	 of	 TGR(mREN2)27	 rats	 were	 compared	 to	 respective	 WT	 quantifications	 in	4	
control,BDL	(2w,	4w)	and	CCl4	(10w)	groups.	Results	are	expressed	as	percentage	of	positive	5	
stained	area.	B)	Quantification	of	hepatic	aSMA	staining.	Positive	aSMA	stainings	of	healthy,	6	
injured	BDL	(2w,	4w)	and	CCl4	(10w)	intoxicated	TGR(mREN2)27	livers	were	compared	with	7	
positive	aSMA	stainings	in	respective	WT	livers.		Results	are	shown	as	percentage	of	positive	8	
stained	area.	C)	Hepatic	protein	expressions	downstream	AT1R.	Protein	expression	levels	of	9	
Jak2,	 pJak2,	 Arhgef1	 and	 aSMA	 were	 detected	 by	 Western	 blots.	 Each	 representative	10	
Western	blot	shows	on	the	left	hand	side,	the	expression	of	hepatic	WT	proteins	and	on	the	11	
right	 hand	 side,	 the	 expression	 of	 hepatic	 TGR(mREN2)27	 proteins.	 Each	 hepatic	 protein	12	
expression	is	illustrated	for	sham	operated,	BDL	(2w,	4w)	and	CCl4	(10w)	intoxicated	rats.	D)	13	
Hepatic	protein	expression	of	AT1R	and	Mas.	 The	hepatic	protein	expression	of	AT1R	and	14	
Mas	 were	 investigated	 by	 Western	 blot.	 Each	 Western	 blot	 shows	 hepatic	 WT	 protein	15	
expressions	 (left)	 and	 hepatic	 TGR(mREN2)27	 protein	 expressions	 (right).	 Protein	16	
expressions	of	AT1R	and	Mas	are	shown	for	healthy	sham	operated,	BDL	(2w,	4w)	and	CCl4	17	
(10w)	 intoxicated	 livers.	E)	mRNA	expressions	of	hepatic	ACE	mRNA	without	and	with	AVE	18	
injection	in	TGR(mREN2)27	rats.	Livers	of	TGR(mREN2)27	rats	were	analyzed	for	ACE	mRNA	19	
expressions	 with	 and	 without	 AVE	 injection.	 Protein	 expression	 levels	 of	 healthy	 control	20	
livers	 and	 injured	 livers	 (BDL,	 CCl4)	were	normalized	 to	healthy	 control	 livers	without	AVE	21	
injection.	 Hepatic	 mRNA	 expressions	 are	 represented	 in	 x-fold	 change.	 F)	 Hepatic	 AT1R	22	
mRNA	 expression	 with	 and	 without	 AVE	 injection	 in	 TGR(mREN2)27	 rats.	 Hepatic	 AT1R	23	
mRNA	expression	of	TGR(mREN2)27	rats	were	normalized	to	control	TGR(mREN2)27	values	24	
and	represented	as	x-fold	change.		Bars	are	illustrated	as	means	±	s.e.m.	Statistical	analyzes;	25	
Mann-Whitney	 t-test.	 */**	 indicates	 p<0.05/p<0.005	 compared	 to	 respective	 WT	 or	26	
TGR(mREN2)27	controls.		27	
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D. Hepatic protein expression of AT1R and Mas 
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E. Hepatic ACE mRNA expression without and 
with AVE injection in TGR(mREN2)27 rats 
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F. Hepatic AT1R mRNA expression without and 
with AVE injection in TGR(mREN2)27 rats 
WT TGR(mREN2)27 
 
AT1R 
 
 
 
Mas 
 
 
 
GAPDH 
 
 
 
AT1R 
 
 
 
Mas 
 
 
 
GAPDH 
 
 
 
AT1R 
 
 
 
Mas 
 
 
 
GAPDH 
 
 
 
AT1R 
 
 
 
Mas 
 
 
 
GAPDH 
40 kDa 
 
 
 
37 kDa 
 
 
37 kDa 
 
 
 
40 kDa 
 
 
37 kDa 
 
 
37 kDa 
 
 
 
40 kDa 
 
 
37 kDa 
 
 
37 kDa 
 
 
 
40 kDa 
 
 
37 kDa 
 
 
37 kDa 
 
 
 
C
C
l 4 
S
ha
m
 
B
D
L 
(2
w
) 
B
D
L 
(4
w
) 
                                   WT           TGR(mREN2)27 
